Literature DB >> 2891137

Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells.

J F Reinhard1, E J Diliberto, O H Viveros, A J Daniels.   

Abstract

Cultures of bovine adrenomedullary chromaffin cells accumulated 1-methyl-4-phenylpyridinium (MPP+) in a time- and concentration-dependent manner by a process that was prevented by desmethylimipramine. The subcellular localization of the incorporated [methyl-3H]MPP+ was examined by differential centrifugation and sucrose density gradient fractionation and was found to be predominantly colocalized with catecholamines in chromaffin vesicles, and negligible amounts were detected within the mitochondrial fraction. When chromaffin cell membranes were made permeable with the detergent digitonin in the absence of calcium, there was no increase in the release of [3H]MPP+, indicating that there is negligible accumulation of the neurotoxin in the cytosol. Simultaneous exposure to digitonin and calcium induced cosecretion of MPP+ and catecholamines. Stimulation of the cells with nicotine released both catecholamines and MPP+ at identical rates and percentages of cellular content in a calcium-dependent manner. Last, when cells were incubated with MPP+ in the presence of tetrabenazine (an inhibitor of vesicular uptake), the chromaffin cell toxicity of MPP+ was potentiated. We submit that the ability of the chromaffin cells to take up and store MPP+ in the chromaffin vesicle prevents the toxin's interaction with other structures and, thus, prevents cell damage. As an extension of this hypothesis, the relative resistance of some brain monoaminergic neurons to the toxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may result from the subcellular sequestration of MPP+ in the storage vesicle.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2891137      PMCID: PMC299498          DOI: 10.1073/pnas.84.22.8160

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

Authors:  K Chiba; A Trevor; N Castagnoli
Journal:  Biochem Biophys Res Commun       Date:  1984-04-30       Impact factor: 3.575

2.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

Authors:  W J Nicklas; I Vyas; R E Heikkila
Journal:  Life Sci       Date:  1985-07-01       Impact factor: 5.037

3.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

Authors:  R E Heikkila; A Hess; R C Duvoisin
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

4.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

5.  Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse.

Authors:  E Sundström; G Jonsson
Journal:  Eur J Pharmacol       Date:  1985-04-16       Impact factor: 4.432

6.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

Authors:  J A Javitch; R J D'Amato; S M Strittmatter; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

7.  Amphetamine, but not reserpine, protects mice against dopaminergic neurotoxicity of MPTP.

Authors:  E Melamed; J Rosenthal; O Cohen; A Uzzan; M Globus
Journal:  Neuropharmacology       Date:  1985-09       Impact factor: 5.250

8.  1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-CH3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice.

Authors:  S K Youngster; R C Duvoisin; A Hess; P K Sonsalla; M V Kindt; R E Heikkila
Journal:  Eur J Pharmacol       Date:  1986-03-18       Impact factor: 4.432

9.  Persistent depletion of striatal dopamine in mice by 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine (MTTP).

Authors:  R W Fuller; D W Robertson; S K Hemrick-Luecke
Journal:  Biochem Pharmacol       Date:  1986-01-15       Impact factor: 5.858

10.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism.

Authors:  S P Markey; J N Johannessen; C C Chiueh; R S Burns; M A Herkenham
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

View more
  17 in total

1.  Selective neurotoxins, chemical tools to probe the mind: the first thirty years and beyond.

Authors:  R M Kostrzewa
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

Review 2.  Current theories on the cause of Parkinson's disease.

Authors:  J W Langston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

3.  Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

Authors:  William Dauer; Nikolai Kholodilov; Miquel Vila; Anne-Cecile Trillat; Rose Goodchild; Kristin E Larsen; Roland Staal; Kim Tieu; Yvonne Schmitz; Chao Annie Yuan; Marcelo Rocha; Vernice Jackson-Lewis; Steven Hersch; David Sulzer; Serge Przedborski; Robert Burke; Rene Hen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-10       Impact factor: 11.205

4.  Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells.

Authors:  Jun Tang Guo; An Qi Chen; Qi Kong; Hua Zhu; Chun Mei Ma; Chuan Qin
Journal:  Cell Mol Neurobiol       Date:  2007-11-06       Impact factor: 5.046

Review 5.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

6.  FosB and ΔFosB expression in brain regions containing differentially susceptible dopamine neurons following acute neurotoxicant exposure.

Authors:  Joseph R Patterson; Elizabeth J Kim; John L Goudreau; Keith J Lookingland
Journal:  Brain Res       Date:  2016-08-24       Impact factor: 3.252

7.  Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.

Authors:  J D Erickson; M K Schafer; T I Bonner; L E Eiden; E Weihe
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

8.  Interaction of 1-methyl-4-phenylpyridinium ion and tyramine with a site putatively involved in the striatal vesicular release of dopamine.

Authors:  A Vaccari; M Del Zompo; F Melis; G L Gessa; Z L Rossetti
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

9.  Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium.

Authors:  Y Liu; A Roghani; R H Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

10.  Effects of MPP+ on catecholamine levels in adrenal glands and heart of rats.

Authors:  M Kujacic; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.